## Matthew Clark

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7350684/publications.pdf Version: 2024-02-01



MATTHEW CLADK

#	Article	IF	CITATIONS
1	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell, 2021, 184, 5432-5447.e16.	28.9	131
2	Type 1 Diabetes: A Chronic Anti-Self-Inflammatory Response. Frontiers in Immunology, 2017, 8, 1898.	4.8	101
3	Therapies to Suppress Î <sup>2</sup> Cell Autoimmunity in Type 1 Diabetes. Frontiers in Immunology, 2018, 9, 1891.	4.8	24
4	RNase L Suppresses Androgen Receptor Signaling, Cell Migration and Matrix Metalloproteinase Activity in Prostate Cancer Cells. International Journal of Molecular Sciences, 2017, 18, 529.	4.1	19
5	Immunological evaluation of the entirely carbohydrate-based Thomsen-Friedenreich – PS B conjugate. Organic and Biomolecular Chemistry, 2016, 14, 3350-3355.	2.8	18
6	The Role of T Cell Receptor Signaling in the Development of Type 1 Diabetes. Frontiers in Immunology, 2020, 11, 615371.	4.8	12
7	Evolving Antibody Therapies for the Treatment of Type 1 Diabetes. Frontiers in Immunology, 2020, 11, 624568.	4.8	11
8	A Multitrait Locus Regulates Sarbecovirus Pathogenesis. MBio, 2022, 13, .	4.1	11
9	Antibody Binding to CD4 Induces Rac GTPase Activation and Alters T Cell Migration. Journal of Immunology, 2016, 197, 3504-3511.	0.8	7
10	Anti-coreceptor therapy drives selective T cell egress by suppressing inflammation-dependent chemotactic cues. JCl Insight, 2016, 1, e87636.	5.0	6
11	Coreceptor therapy has distinct short- and long-term tolerogenic effects intrinsic to autoreactive effector T cells. ICI Insight. 2021. 6	5.0	1